Alembic Pharmaceuticals Ltd Financials
Company Logo

Alembic Pharmaceuticals Ltd Financial Statement

Alembic Pharmaceuticals Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Sep 2024
Revenue1609.28
Operating Expense1320.86
Net Profit165.78
Net Profit Margin10.30
Earning Per Share8.43
EBIDTA288.42
Effective Tax Rate11.87
Invest in Alembic Pharmaceuticals Ltd
₹0 Brokerage*
Open Demat Account
*By signing up you agree to our Terms and Conditions

Alembic Pharmaceuticals Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual5,874.06
Operating Expenses Annual4,875.54
Operating Profit Annual1,029.84
Interest Annual54.47
Depreciation271.14
Net Profit Annual666.48
Tax Annual37.75

Alembic Pharmaceuticals Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning21.67
Cash Flow from Operations772.77
Cash Flow from Investing-329.02
Cash Flow from Financing-445.29
Cash Flow at the End20.13

Alembic Pharmaceuticals Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)17.53
PBIT Margin (%)12.92
PBT Margin (%)12.68
Net PROFIT Margin (%)11.35
Return On Networth / Equity (%)14.30
Return On Networth /Employed (%)14.13
Return On Assets (%)12.37
Total Debt / Equity (X)0.13
Asset Turnover Ratio (%)1.09

Alembic Pharmaceuticals Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual2,535.66
Total Current Assets Annual2,988.55
Non Current Assets Annual3,409.99
Total Shareholders Funds Annual4,908.91
Total Assets Annual6,398.54

Alembic Pharmaceuticals Ltd Earning Calls

EPS (INR)

Expected

7.81

Reported

7.79

Surprise

-0.26%

Jun 2024

EPS beaten by -0.26%

Mar 2024

EPS beaten by -0.15%

Dec 2023

EPS beaten by -6.50%

Get Your FAQs Right

As of Nov 23, 2024, Alembic Pharmaceuticals Ltd has a market capitalization of 19,309.38 Cr. Value Research classifies it as a Large-Cap company.
Yes, Alembic Pharmaceuticals Ltd is debt-free with a debt-to-equity ratio of 0.10.
In FY 2023 , Alembic Pharmaceuticals Ltd recorded a total revenue of approximately 5,874.06 Cr marking a significant milestone in the company's financial performance.
Alembic Pharmaceuticals Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.1% and 0.1% annually, respectively..
Alembic Pharmaceuticals Ltd's current PE ratio is 28.97.
Alembic Pharmaceuticals Ltd's ROCE averaged 11.0% from the FY ending March 2022 to 2024, with a median of 11.3%. It peaked at 14.0% in March 2024, reflecting strong capital efficiency over the period..
Alembic Pharmaceuticals Ltd's latest EBIT is Rs. 758.70 Cr, surpassing the average EBIT of Rs. 609.55 Cr over the 5 years..